From the New England Journal of Medicine quot Currently after a drug is approved for marketing we rely on a voluntary reporting system based on the assumption that a drug is safe It is remarkable that at a time when the technology for collecting and analyzing large amounts of data is readily available an independent comprehensive and systematic program of post-marketing drug surveillance does not exist quot
Bookmark to:
